GRTS Gritstone bio Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GRTS

Price (delayed)

$0.9627

Market cap

$94.41M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$133.9M

Gritstone bio, Inc., a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, ...

Highlights
The EPS is up by 9% year-on-year and by 3.2% since the previous quarter
The revenue has soared by 60% from the previous quarter but it has contracted by 18% YoY
GRTS's gross profit has soared by 60% QoQ but it is down by 18% YoY
Gritstone bio's debt has surged by 160% YoY and by 10% QoQ
The equity has dropped by 70% year-on-year and by 30% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://gritstonebio.com
Peers: OMER OMGA

Key stats

What are the main financial stats of GRTS
Market
Shares outstanding
98.07M
Market cap
$94.41M
Enterprise value
$133.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.77
Price to sales (P/S)
6.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.19
Earnings
Revenue
$16.34M
EBIT
-$134.45M
EBITDA
-$112.8M
Free cash flow
-$126.22M
Per share
EPS
-$1.2
Free cash flow per share
-$1.09
Book value per share
$0.54
Revenue per share
$0.14
TBVPS
$1.54
Balance sheet
Total assets
$177.77M
Total liabilities
$125.92M
Debt
$104.78M
Equity
$51.85M
Working capital
$60.1M
Liquidity
Debt to equity
2.02
Current ratio
3.2
Quick ratio
2.98
Net debt/EBITDA
-0.35
Margins
EBITDA margin
-690.2%
Gross margin
100%
Net margin
-847.3%
Operating margin
-854.5%
Efficiency
Return on assets
-69.5%
Return on equity
-147.2%
Return on invested capital
-62.9%
Return on capital employed
-89.4%
Return on sales
-822.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GRTS stock price

How has the Gritstone bio stock price performed over time
Intraday
10.66%
1 week
18.85%
1 month
-19.1%
1 year
-61.18%
YTD
-52.81%
QTD
-62.54%

Financial performance

How have Gritstone bio's revenue and profit performed over time
Revenue
$16.34M
Gross profit
$16.34M
Operating income
-$139.65M
Net income
-$138.49M
Gross margin
100%
Net margin
-847.3%
The revenue has soared by 60% from the previous quarter but it has contracted by 18% YoY
GRTS's gross profit has soared by 60% QoQ but it is down by 18% YoY
The company's operating margin fell by 42% YoY but it rose by 38% QoQ
Gritstone bio's net margin has decreased by 41% YoY but it has increased by 38% QoQ

Growth

What is Gritstone bio's growth rate over time

Valuation

What is Gritstone bio stock price valuation
P/E
N/A
P/B
1.77
P/S
6.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.19
The EPS is up by 9% year-on-year and by 3.2% since the previous quarter
The equity has dropped by 70% year-on-year and by 30% since the previous quarter
GRTS's P/B is 23% below its last 4 quarters average of 2.3 and 16% below its 5-year quarterly average of 2.1
The stock's price to sales (P/S) is 79% less than its 5-year quarterly average of 33.1 and 63% less than its last 4 quarters average of 18.5
The revenue has soared by 60% from the previous quarter but it has contracted by 18% YoY

Efficiency

How efficient is Gritstone bio business performance
The ROE has dropped by 103% year-on-year and by 31% since the previous quarter
The return on sales has declined by 39% year-on-year but it is up by 38% since the previous quarter
Gritstone bio's ROA has decreased by 31% YoY and by 8% from the previous quarter
The ROIC is up by 18% year-on-year

Dividends

What is GRTS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRTS.

Financial health

How did Gritstone bio financials performed over time
The company's total assets is 41% higher than its total liabilities
The company's total liabilities has surged by 80% YoY and by 11% QoQ
GRTS's quick ratio is down by 41% year-on-year and by 18% since the previous quarter
Gritstone bio's debt is 102% higher than its equity
Gritstone bio's debt has surged by 160% YoY and by 10% QoQ
The equity has dropped by 70% year-on-year and by 30% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.